Lexeo Therapeutics Q3 Earnings Call Highlights
Lexeo Therapeutics shares surge 25% on interim data for LX2020 gene therapy
Lexeo Therapeutics Reports LX2020 Gene Therapy Trial Data and Outlines Potential FDA Accelerated Approval Pathway
Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results
Lexeo Therapeutics Announces Interim Data From Its Ongoing HEROIC-PKP2 Phase I/II Clinical Trial Of LX2020 For Treatment Of PKP2 Arrhythmogenic Cardiomyopathy; Across Ten Participants, Including Nine With At Least 12 Months Of Follow-up, Treatment With LX2020 Was Generally Well Tolerated
Lexeo Therapeutics Q3 EPS $(0.43) Misses $(0.33) Estimate
Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026
Lexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in November
Lexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 Readout
Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy - Slideshow
Lexeo Therapeutics Eyes NSVT Data as Key Test for LX2020 Gene Therapy
Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy Transcript
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)
Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript
Lexeo Therapeutics, Inc. (LXEO) Mantle Therapeutics Inc. - M&A Call - Slideshow
Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.